iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by Peapod Lane Capital LLC

Peapod Lane Capital LLC raised its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 24.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 135,655 shares of the company's stock after purchasing an additional 26,802 shares during the period. Peapod Lane Capital LLC owned about 0.36% of iTeos Therapeutics worth $810,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of iTeos Therapeutics during the fourth quarter valued at $42,000. Virtus ETF Advisers LLC grew its holdings in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after acquiring an additional 3,293 shares in the last quarter. Forefront Analytics LLC purchased a new position in iTeos Therapeutics during the 4th quarter valued at about $85,000. Graham Capital Management L.P. purchased a new position in iTeos Therapeutics during the 4th quarter valued at about $85,000. Finally, Wells Fargo & Company MN raised its holdings in shares of iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after purchasing an additional 2,402 shares in the last quarter. 97.16% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ITOS shares. Piper Sandler reissued an "overweight" rating and set a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partnrs downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. HC Wainwright lowered iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $15.00 to $8.00 in a research report on Tuesday, May 13th. Finally, Wedbush lowered iTeos Therapeutics from an "outperform" rating to a "neutral" rating and lifted their target price for the company from $10.00 to $12.00 in a research note on Wednesday, May 28th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $15.86.

iTeos Therapeutics Stock Up 0.8%

Shares of iTeos Therapeutics stock traded up $0.08 during trading on Friday, reaching $10.29. The company's stock had a trading volume of 859,526 shares, compared to its average volume of 697,441. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $18.13. The company has a 50-day simple moving average of $9.27 and a two-hundred day simple moving average of $7.83. The company has a market cap of $393.80 million, a price-to-earnings ratio of -3.38 and a beta of 1.49.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. As a group, analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Insider Activity at iTeos Therapeutics

In other news, Director David Hallal sold 38,228 shares of iTeos Therapeutics stock in a transaction on Friday, June 6th. The shares were sold at an average price of $10.24, for a total transaction of $391,454.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the sale, the insider directly owned 2,108,594 shares in the company, valued at $16,995,267.64. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,939,307 shares of company stock valued at $16,202,116. Company insiders own 12.50% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.